Management

CABERNET Clinical Study

The objective of the CABERNET Trial is to evaluate the safety and effectiveness of focal delivery of radiation for the treatment of subfoveal choroidal neovascularization (CNV) associated with wet age related macular degeneration (AMD). The CABERNET Trial is a randomized, prospective, controlled, study of the NeoVista Ophthalmic System for the treatment of subfoveal choroidal neovascularization associated with wet age-related macular degeneration.

Hope for the future? New clinical trials.

NeoVista, Inc. is a company that is developing an intraocular epiretinal radiation device intended for the treatment of the wet form of age-related macular degeneration. If you, or someone you know, are interested in participating in the CABERNET Trial, please follow the link below: